A systematic literature review and bayesian meta-analysis of oral vancomycin primary prophylaxis for Clostridioides difficile infection in stem cell transplant patients
Open Access
- 14 October 2025
- journal article
- review article
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e265
Abstract
Introduction: Clostridioides difficile infection (CDI) is common among patients undergoing hematopoietic stem cell transplantation (HSCT). Oral vancomycin prophylaxis may effectively prevent CDI in certain populations. We investigated the effectiveness of oral vancomycin primary prophylaxis in preventing CDI in HSCT patients. Methods: We searched six databases from inception to March 21, 2025, for studies comparing the incidence of CDI in HSCT patients who received oral vancomycin primary prophylaxis versus those who did not. We built a Bayesian random-effects model for meta-analysis. The primary outcome was the incidence of CDI. Secondary outcomes included incidence of positive vancomycin-resistant Enterococcus cultures, blood stream infections, graft-vs-host disease, and length of hospital stay. We also assessed for heterogeneity and publication bias using Robust Bayesian Meta-Analyses. Results: Six studies met inclusion criteria with a total of 1,236 patients. Four of the studies were of fair to good quality. Oral vancomycin primary prophylaxis reduced the incidence of CDI during hospitalization (OR 0.31; 95%CrI 0.16–0.59). Studies were weakly heterogeneous but had strong publication bias. Oral vancomycin primary prophylaxis reduced the odds of CDI by 12% after accounting for publication bias (OR 0.88; 95%CrI 0.32–1.16), although this reduction was not statistically significant. Secondary outcomes were similar in both groups. Conclusion: Oral vancomycin primary prophylaxis prevented CDI in HSCT patients without significantly affecting secondary outcomes. However, after controlling for publication bias, these findings were no longer significant. Further studies are needed to provide stronger evidence for or against this intervention, assess long-term safety, and assess potential effects on antimicrobial resistance.Keywords
This publication has 40 references indexed in Scilit:
- Effectiveness of oral vancomycin as prophylaxis against Clostridioides difficile infection in hematopoietic stem cell transplant patientsAntimicrobial Stewardship & Healthcare Epidemiology, 2024
- Using Oral Vancomycin As Prophylaxis Against Clostridioides Difficile Infection in Stem Cell Transplant Recipients Is Associated with Increased Gram Negative BacteremiaTransplantation and Cellular Therapy, 2024
- European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adultsClinical Microbiology and Infection, 2021
- Effect of Vancomycin on the Gut Microbiome and Plasma Concentrations of Gut-Derived Uremic SolutesKidney International Reports, 2021
- Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy PopulationInfectious Disease Clinics of North America, 2019
- Risk of Clostridium difficile Infection in Hematology-Oncology Patients Colonized With Toxigenic C. difficileInfection Control & Hospital Epidemiology, 2017
- Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic StrainsTransplantation and Cellular Therapy, 2016
- Publication bias in meta‐analyses from the Cochrane Database of Systematic ReviewsStatistics in Medicine, 2015
- Clostridium Difficile Colonization and Disease in Patients Undergoing Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2014
- Changing Epidemiology of Clostridium difficile–Associated Disease during Stem Cell TransplantationTransplantation and Cellular Therapy, 2013